Navigation Links
Artificial pump effectively backs up failing hearts
Date:4/2/2009

Patients with severe heart failure can be bridged to eventual transplant by a new, smaller and lighter implantable heart pump, according to a just-completed study of the device. Results of this third-generation heart assist device were reported at the 58th annual meeting of the American College of Cardiology on March 30.

The device, called a left ventricular assist device (LVAD), is the latest generation of heart assist devices. The LVAD was tested at five main sites: Washington University School of Medicine in St. Louis, the University of Minnesota, Mt. Sinai School of Medicine, Inova Fairfax Hospital and the University of Pittsburgh.

"LVADs have allowed us to support patients until they can receive a heart transplant, so they are called a bridge to transplant," says Gregory Ewald, M.D., a Washington University cardiologist at Barnes-Jewish Hospital and medical director of the Heart Failure, Cardiac Transplantation and Total Artificial Heart Program. "For patients whose hearts are failing and are awaiting transplantation, these devices can be lifesavers. Washington University is the only medical center in the region where patients can receive these devices at this time."

In addition to Ewald, associate professor of medicine, lead investigators in the trial included Nader Moazami, M.D., associate professor of surgery and surgical director of the Cardiac Transplantation and Total Artificial Heart Program at Washington University, and Andrew Boyle, M.D., associate professor of medicine at the University of Minnesota and medical director of Heart Failure, Cardiac Transplantation and Mechanical Circulatory Support. Boyle presented the findings at the ACC meeting.

An LVAD is implanted inside the chest cavity near the heart and is connected to the heart's left ventricle (pumping chamber). It assists the patient's weakened or damaged ventricle in pumping blood through the body. By restoring a normal blood flow, the device improves patients' health. Because it is powered by portable battery packs, patients usually go home while they wait for a heart transplant.

The LVAD used in this study, the VentrAssist, is termed a third-generation heart assist device. Measuring 2.5-inches across and weighing 10 ounces, the pump is considered an improvement over earlier devices because its size and light weight make it suitable for small adults and children. In addition, its pumping mechanism has no contacting parts for improved durability.

Patients who received the LVAD in the study were approved and listed for cardiac transplantation. The study considered the device successful if a patient survived until heart transplantation or survived at least 180 days after the device was implanted and remained qualified for heart transplantation. Eighty-five percent of patients met this measure of success.

Out of 98 patients who received the device, 60 were transplanted, 19 continued to be supported with the device and 19 died. The median time on LVAD support was 131 days. Adverse events reported during the trial included stroke and bleeding, and the number and type of adverse events was similar to other LVADs but better than that of first-generation VAD devices.

Answering standardized questionnaires for patients with heart failure, they reported a significantly improved quality of life after receiving the device, indicating that their heart failure was less apt to interfere with everyday activities such as housework, hobbies or sleeping or to affect their mood, ability to concentrate or energy level.

"Before implantation of the device, 80 percent of these patients were rated class four on the New York Heart Association scale they were short of breath at rest," Ewald says. "But by six months, 84 percent were in class one or two, meaning their heart failure symptoms were minimal or mild. All of them were able to go home with the device, and that allowed them to rehabilitate themselves their nutrition improved and they were in better shape, making them better candidates for heart transplantation."

The VentrAssist device pumps blood in a continuous flow in contrast to earlier heart assist pumps that pumped blood in pulses. It contains a spinning rotor that is suspended by blood within the pump housing and magnetically rotated. Since the impeller blades don't touch any part of the pump, the chance of damage to blood cells is lessened. With only one moving part, the pump is resistant to wear.

The positive results from this clinical study mean the VentrAssist will be submitted to the U.S. Food and Drug Administration for approval for use as a bridge to heart transplant. In the interim, Washington University School of Medicine will continue to provide the device to patients as part of a clinical trial.


'/>"/>

Contact: Gwen Ericson
ericsong@wustl.edu
314-286-0141
Washington University School of Medicine
Source:Eurekalert

Related medicine news :

1. Researchers Successfully Create Computer-Simulated Model for Evaluating Artificial Pancreas
2. Artificial disc replacement as good or better than spinal fusion surgery
3. New Technology May Boost Artificial Arms
4. Weizmann Institute scientists create working artificial nerve networks
5. Ringling Bros. and Barnum & Bailey(R) Proudly Announces Its First Elephant Calf Born From Artificial Insemination
6. Bi-Coastal Pharmaceutical Corp. Acquires U.S. Marketing Rights to Aquoral(TM) Artificial Saliva Product
7. AMA Supports Ban of Artificial Trans Fats in Restaurants and Bakeries Nationwide
8. Archus Orthopedics Performs First Facet Replacement Procedure With an Artificial Disc
9. Breast Cancer Action Targets Yoplait in Think Before You Pink Campaign; Calls for Yogurt Without Artificial Hormones
10. Researchers design model for automated, wearable artificial kidney
11. Photos: Los Angeles Non Profit Teams With US Troops Stationed in Baghdad and Buaytha in Bringing a 5-Year-Old Blind Iraqi Girl, Whose Father Stands Beside US Combat Team Against Al Qaeda, to the US for a Groundbreaking Artificial Corneal Transplant Surger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... actively feeding the Frederick area economy by obtaining investment capital for emerging technology ... past 2½ years that have already resulted in more than a million dollars ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
(Date:6/24/2016)... , June 24, 2016   Bay Area ... Network,s Dean Center for Tick Borne Illness ... and Rehabilitation, MIT Hacking Medicine, University of California, ... today announced the five finalists of Lyme ... disease.  More than 100 scientists, clinicians, researchers, entrepreneurs, ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, ... -based mobile pulmonary function testing company, is now able to perform ... developed by ndd Medical Technologies , Inc. ... in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL ... can get any needed testing done in the comfort of her ...
Breaking Medicine Technology: